TherapeuticsMD Inc. Common Stock (TXMD)
Stock · NASDAQ · Health Care
$1.9as of 10/16/2026
Price chart
Active signals
TXMD Signal Track Record
How signals performed across all stocks →What TXMD's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 43 | -4.8% | 40% | September 21, 2026 |
| Bollinger Band BreakdownActive now | 24 | -1.1% | 42% | September 25, 2026 |
| Bollinger Band Breakout | 14 | -0.4% | 50% | August 25, 2026 |
| 200-Day Moving Average TouchActive now | 4 | -5.9% | 25% | September 21, 2026 |
| Any 20-session window (baseline) | -3.0% | 39% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About TXMD
TherapeuticsMD, Inc. operates as a pharmaceutical royalty company in the United States and internationally. Its products portfolio includes IMVEXXY for the treatment of moderate-to-severe dyspareunia, a symptom of vulvar and vaginal atrophy due to menopause; BIJUVA to treat moderate-to-severe vasomotor symptoms due to menopause in women with a uterus; and ANNOVERA, a ring-shaped contraceptive vaginal system. The comp…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 1
- Website
- www.therapeuticsmd.com/
Fundamentals
- 1-day range
- $1.88$1.95
- Market cap
- $24.19M
- P/E (trailing)
- 135.01
- P/E (forward)
- 5.43
- EPS (trailing)
- $-0.02
- Dividend yield
- —
- Beta
- 0.65
- Avg. volume
- 23.3K
How TherapeuticsMD Inc. Common Stock Makes Money
Where the revenue actually goes — FY2024 annual results
Source: 10-K filed Mar 27, 2025 · via SEC EDGAR / Finnhub
TherapeuticsMD Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- TXMDTherapeuticsMD Inc. Common Stock$1.9▼ 1.55%Market cap $24.19MP/E 135.01$1.03$2.95
- IGCIGC Pharma Inc. Common Stock$0.25▲ 0.00%Market cap $23.94MP/E —$0.235$0.4508
- LGVNLongeveron Inc. Class A Common Stock$1.39▼ 7.33%Market cap $24.44MP/E —$1.69$12.3
- ATNMActinium Pharmaceuticals Inc. (Delaware) Common Stock$1.13▲ 6.60%Market cap $24.69MP/E 2.95$0.7351$1.74
- AYTUAytu BioPharma Inc. Common Stock$2.04▲ 1.49%Market cap $25.01MP/E —$1.8$3.07
- TVRDTvardi Therapeutics Inc. Common Stock$1.01▼ 5.61%Market cap $23.02MP/E —$0.93$7.23
- OBXObsidian Therapeutics Inc. Common Stock$11.77▼ 3.52%Market cap $22.74MP/E —$11.79$49.97
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| TXMD TherapeuticsMD Inc. Common Stock | $24.19M | 135.01 | $1.9 | ▼ 1.55% | $1.03$2.95 |
| IGC IGC Pharma Inc. Common Stock | $23.94M | — | $0.25 | ▲ 0.00% | $0.235$0.4508 |
| LGVN Longeveron Inc. Class A Common Stock | $24.44M | — | $1.39 | ▼ 7.33% | $1.69$12.3 |
| ATNM Actinium Pharmaceuticals Inc. (Delaware) Common Stock | $24.69M | 2.95 | $1.13 | ▲ 6.60% | $0.7351$1.74 |
| AYTU Aytu BioPharma Inc. Common Stock | $25.01M | — | $2.04 | ▲ 1.49% | $1.8$3.07 |
| TVRD Tvardi Therapeutics Inc. Common Stock | $23.02M | — | $1.01 | ▼ 5.61% | $0.93$7.23 |
| OBX Obsidian Therapeutics Inc. Common Stock | $22.74M | — | $11.77 | ▼ 3.52% | $11.79$49.97 |
P/E shows — for peers not currently carrying a live signal of their own.
Institutional Ownership
March 31, 2026
- Total shares held
- 3.90M
- Total value held
- $7.86M
- Institutional holders
- 47
- Unknown1.19M
- Unknown635.2K
- Unknown420.4K
- Unknown353.7K
- Unknown345.9K
- Unknown209.2K
- Unknown146.2K
- Unknown129.2K
- Unknown115.1K
- Unknown109.8K
See the full, filterable feed with live charts on the MarketWall dashboard.